Adverse effects of BCG vaccine 1173 P2 in Iran: A meta-analysis

Authors
Saied Mostaan 1
Bahador Yazdanpanah 2
Rasool Moukhah 2
Hamid Reza Hozouri 2
Manouchehr Rostami 2
Mohsen Khorashadizadeh 3
Javad Zerehsaz 4
Ramin Pirhajati Mahabadi 4
Arya Saadi 5
Hossein Khanahmad 6
Mohammad Pooya 1
1 Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
2 Department of BCG, Production and Research Complex, Pasteur Institute of Iran, Tehran, Iran
3 Department of Cellular and Molecular Biology, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran
4 Department of Bacteriology, Medical School, Tarbiat Modarres University, Tehran, Iran
5 Technical Office, Pasteur Institute of Iran, Tehran, Iran
6 Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Although in the last two decades the World Health Organization (WHO) has introduced tuberculosis as “a threat to global”, the vaccination with the Mycobacterium bovis Bacillus Calmette-Guerin (BCG) is the only way for the prevention of this fatal infectious disease. Despite of the efficacy of BCG vaccine especially against infants' meningitis, it has still some limitations due to a variety of adverse effects. Many studies have evaluated the side effects of different strains of BCG vaccines in different countries. In Iran, some studies have been done so far to evaluate the adverse effects of 1173 P2 strain which is used for BCG vaccination. Each of these studies have used different standardization and sampling methods. This review will survey all studies that have been published about adverse effects of 1173 P2 strain of BCG vaccine in Iran using data mining methods.
Keywords
Bacillus calmette-guerin
side effects
safety
1173P2
1.
World Health Organization (2006). TB country profile/Iran.  Back to cited text no. 1
    
2.
Hestvik AL, Hmama Z, Av-Gay Y. Mycobacterial manipulation of the hostcell. FEMS Microbiol Rev 2005;29:1041-50.  Back to cited text no. 2
    
3.
Rook GA, Seah G, Ustianowski A. M.tuberculosis: Immunobiology and vaccination. Eur Respir J 2001;17:537-57.  Back to cited text no. 3
    
4.
Behr MA. BCG—different strains, different vaccines? Lancet Infect Dis 2002;2:86-92.  Back to cited text no. 4
    
5.
Weill-Halle B, Turpin R. Premiers essays de vaccination antituberculeuse del'enfant parle Bacille Ca;mette-Guerin(BCG). Bull Mem Soc Med Hosp de Paris 1925;49:1589-601.  Back to cited text no. 5
    
6.
AfsharPaiman S, Siadati A, Mamishi S, Tabatabaie P, Khotaee G. Disseminated Mycobacteriumbovis iInfection after BCG vaccination. Iran J Allergy Asthma Immunol 2006;5:133-7.  Back to cited text no. 6
    
7.
Karimi A, Nateghian A, Mamishi S. 8 case report of disseminated BCG during 1998-2002 in Tehran Pediatric Center. Maz Uni Med Sci 2003;13:38.  Back to cited text no. 7
    
8.
Seyfhashemi M, Hemati A, Mazaheri M, Azarbarin A, Hamedi P. Complications of BCG vaccination in children. Iran J Pediatr 2005;3:209-14.  Back to cited text no. 8
    
9.
Ghoreishi FE. Case report of BCGitis affected right muscle of abdomen. J Isfahan Med School 2003;27:71:57  Back to cited text no. 9
    
10.
Mansouri D, Adimi P, Mirsaeidi M, Mansouri N, Khalilzadeh S, Masjedi MR, et al. Inherited disorders of the IL-12-IFN-γ axis in patients with disseminated BCG infection. Eur J Pediatr 2005;164:753-7.  Back to cited text no. 10
    
11.
Zadie MT, Vahedi A, Ilkhanizadeh B, Norouzinia F, Ghavam F. Post BCG vaccination Xanthogranuloma. Urm Med J 2006;17138-40.  Back to cited text no. 11
    
12.
Hematyar M, Chohdari A. Prevalence of BCG adenitis in infants vaccinated at birth. The Journal of Qazvin Univ Med Sci 2006;9:42-6.  Back to cited text no. 12
    
13.
Alborzi A, Mostafavi N. Retropretoneal abscess due to disseminated bacilli Calmette-Guerin infection. Jpn J Infect Dis 2007;60:392-3.  Back to cited text no. 13
    
14.
Ghadiri K, Afsharian M, Vaziri S, Mansouri F, Namdari S. Kordestan Univ Med Sci J 2007;12:91-6.  Back to cited text no. 14
    
15.
Rezai MS, Khotaei G, Mamishi S, Kheirkhah M, Parvaneh N. Disseminated Bacillus Calmette–Guerin Infection after BCG Vaccination. J Trop Pediatr 2008;54:413-6.  Back to cited text no. 15
    
16.
Behjati M, Ayatollahi J. Post BCG Lymphadenitis in Vaccinated Infants in Yazd, Iran. I J Pediatr 2008;18:351-6.  Back to cited text no. 16
    
17.
Sadeghi-Shabestari M, Vesal S, Jabbarpour-Bonyadi M, de Villatay JP, Fischer A, Rezaei N. Novel RAG2 Mutation in a Patient with T– B– Severe Combined Immunodeficiency and Disseminated BCG Disease. J Investig Allergol Clin Immunol 2009;19:494-6.  Back to cited text no. 17
    
18.
Movahedi Z, Norouzi S, Mamishi S, Rezaei N. BCGiosis as a presenting feature of a child with chronic granulomatous disease. Braz J Infect Dis 2011;15:83-6.  Back to cited text no. 18
    
19.
Jadali F, Karimi A, Armin S, Gharib A, Fallah F, Sharifian M, et al. Detection of Disseminated Mycobactrial Infection Due to BCG Vaccination (BCGosis) in 4 Suspected Infant Autopsies by PCR Method. Iran J Pathol 2007;2:89-93.  Back to cited text no. 19
    
20.
Farshchian M, Saba MS. Adenitis due to BCG vaccination. Hakim Res J 1999;22:83-7.  Back to cited text no. 20
Advanced Biomedical Research
Volume 2016, june
June 2016
Pages 1-4